Prosight Management as of March 31, 2018
Portfolio Holdings for Prosight Management
Prosight Management holds 31 positions in its portfolio as reported in the March 2018 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Shire | 13.7 | $22M | 146k | 149.39 | |
| Allergan | 10.0 | $16M | 95k | 168.29 | |
| Macrogenics (MGNX) | 7.0 | $11M | 445k | 25.16 | |
| Sabra Health Care REIT (SBRA) | 6.4 | $10M | 580k | 17.65 | |
| Achaogen | 5.4 | $8.6M | 661k | 12.95 | |
| Teligent | 5.2 | $8.3M | 2.5M | 3.36 | |
| Almost Family | 4.7 | $7.6M | 135k | 56.00 | |
| Reata Pharmaceuticals Inc Cl A | 3.8 | $6.1M | 298k | 20.51 | |
| CIGNA Corporation | 3.4 | $5.4M | 32k | 167.73 | |
| Sierra Oncology | 3.3 | $5.3M | 2.5M | 2.07 | |
| Eiger Biopharmaceuticals | 3.3 | $5.2M | 531k | 9.85 | |
| BioMarin Pharmaceutical (BMRN) | 3.2 | $5.1M | 63k | 81.07 | |
| Dex (DXCM) | 3.0 | $4.8M | 65k | 74.15 | |
| Cidara Therapeutics Inc Common Stock Usd 0.0001 | 3.0 | $4.7M | 1.2M | 4.00 | |
| Arena Pharmaceuticals | 3.0 | $4.8M | 120k | 39.50 | |
| Pieris Pharmaceuticals | 2.4 | $3.8M | 564k | 6.82 | |
| Iovance Biotherapeutics (IOVA) | 2.2 | $3.5M | 210k | 16.90 | |
| Inogen Inc put | 2.1 | $3.3M | 27k | 122.84 | |
| Quotient | 2.0 | $3.2M | 682k | 4.71 | |
| AVEO Pharmaceuticals | 1.9 | $3.0M | 1.0M | 2.90 | |
| Clovis Oncology | 1.7 | $2.6M | 50k | 52.80 | |
| Civitas Solutions | 1.6 | $2.5M | 164k | 15.40 | |
| Centene Corporation (CNC) | 1.6 | $2.5M | 23k | 106.87 | |
| Clovis Oncology | 1.5 | $2.4M | 46k | 52.80 | |
| Paratek Pharmaceuticals | 1.2 | $1.9M | 149k | 13.00 | |
| Kindred Healthcare | 0.9 | $1.5M | 162k | 9.15 | |
| Nabriva Therapeutics | 0.8 | $1.2M | 243k | 5.03 | |
| Noveliontherapeuti.. | 0.5 | $816k | 233k | 3.50 | |
| Uniqure Nv (QURE) | 0.5 | $801k | 34k | 23.49 | |
| Bellicum Pharma | 0.4 | $696k | 106k | 6.56 | |
| Ampio Pharmaceuticals | 0.2 | $378k | 111k | 3.40 |
